[1] Ryu JM, Lee HJ, Yoon TI, et al. Breast cancer-specific mortality in small-sized tumor with node-positive breast cancer: a nation-wide study in Korean breast cancer society[J]. Breast Cancer Res Treat, 2016,159(3):489-498. DOI: 10.1007/s10549-016-3943-4.
[2] Yezhelyev M, Yacoub R, O'Regan R. Inorganic nanoparticles for predictive oncology of breast cancer[J]. Nanomedicine (Lond), 2009,4(1):83-103. DOI: 10.2217/17435889.4.1.83.
[3] Wu S, Wen F, Li Y, et al. PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma[J]. Tumour Biol, 2016,37(7):8799-8809. DOI: 10.1007/s13277-015-4691-5.
[4] Vilchèze C, Jacobs WR. Resistance to isoniazid and ethionamide in mycobacterium tuberculosis: genes, mutations, and causalities[J]. Microbiol Spectr, 2014,2(4):MGM2-0014-2013. DOI: 10.1128/microbiolspec.MGM2- 0014-2013.
[5] Zhu B, Liu GT, Zhao YM, et al. Chemosensitizing multiple drug resistance of human carcinoma by Bicyclol involves attenuated p-glycoprotein, GST-P and Bcl-2[J]. Cancer Biol Ther, 2006,5(5):536-543. DOI: 10.4161/cbt.5.5.2655.
[6] Ficociello G, Zanni E, Cialfi S, et al. Glutathione S-transferase ϴ-subunit as a phenotypic suppressor of pmr1Δ strain, the Kluyveromyces lactis model for Hailey-Hailey disease[J]. Biochim Biophys Acta, 2016,1863(11):2650-2657. DOI: 10.1016/j.bbamcr. 2016. 08.002.
[7] Leonel C, Gelaleti GB, Jardim BV, et al. Expression of glutathione, glutathione peroxidase and glutathione S-transferase pi in canine mammary tumors[J]. BMC Vet Res, 2014,10:49. DOI: 10.1186/1746-6148-10-49.
[8] Alpert LC, Schecter RL, Berry DA, et al. Relation of glutathione S-transferase alpha and mu isoforms to response to therapy in human breast cancer[J]. Clin Cancer Res, 1997,3(5):661-667.
[9] Yan F, Jiang Y, Li YM, et al. Reversal of P-glycoprotein and multidrug resistance-associated protein 1 mediated multidrug resistance in cancer cells by HZ08 Isomers, tetrataisohydroquinolin derivatives[J]. Biol Pharm Bull, 2008,31(6):1258-1264. DOI: 10.1248/bpb.31.1258.
[10] Awasthi S, Srivastava SK, Ahmad F, et al. Interactions of glutathione S-transferase-pi with ethacrynic acid and its glutathione conjugate[J]. Biochim Biophys Acta, 1993,1164(2):173-178. DOI: 10.1016/0167-4838(93)90245-m.
[11] Fletcher ME, Boshier PR, Wakabayashi K, et al. Influence of glutathione-S-transferase (GST) inhibition on lung epithelial cell injury: role of oxidative stress and metabolism[J]. Am J Physiol Lung Cell Mol Physiol, 2015,308(12):L1274-285. DOI: 10.1152/ajplung.00220.2014.
[12] Zhang YT, Shen LN, Zhao JH, et al. Evaluation of psoralen ethosomes for topical delivery in rats by using in vivo microdialysis[J]. Int J Nanomedicine, 2014,9:669-678. DOI: 10.2147/IJN.S57314.
[13] Jiang Z, Xiong J. Induction of apoptosis in human hepatocarcinoma SMMC-7721 cells in vitro by psoralen from Psoralea corylifolia[J]. Cell Biochem Biophys, 2014,70(2):1075-81. DOI: 10.1007/s12013-014-0025-2.
[14] Liu Y, Zhang G, Liao Y, et al. Binding characteristics of psoralen with trypsin: Insights from spectroscopic and molecular modeling studies[J]. Spectrochim Acta A Mol Biomol Spectrosc, 2015,151:498-505. DOI: 10.1016/j.saa.2015.07.018.
[15] Prabha C, Maheshwari DK, Bajpai VK. Diverse role of fast growing rhizobia in growth promotion and enhancement of psoralen content in Psoralea corylifolia L[J]. Pharmacogn Mag, 2013,9 Suppl 1:S57-65. DOI: 10.4103/0973-1296.117870.
[16] Wang X, Cheng K, Han Y, et al. Effects of psoralen as an anti-tumor agent in human breast cancer MCF-7/ADR cells[J]. Biol Pharm Bull, 2016,39(5):815-822. DOI: 10.1248/bpb.b15-00957.
[17] Hsieh MJ, Chen MK, Yu YY, et al. Psoralen reverses docetaxel-induced multidrug resistance in A549/D16 human lung cancer cells lines[J]. Phytomedicine, 2014,21(7):970-977. DOI: 10.1016/j.phymed.2014.03.008.
[18] Jiang J, Wang X, Cheng K, et al. Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells[J]. Mol Med Rep, 2016,13(6):4745-4750. DOI: 10.3892/mmr.2016.5098.
[19] Zhu BS, Xing CG, Lin F, et al. Blocking NF-κB nuclear translocation leads to p53-related autophagy activation and cell apoptosis[J]. World J Gastroenterol, 2011,17(4):478-487. DOI: 10.3748/wjg.v17.i4.478.
[20] Ouaissi A, Ouaissi M, Sereno D. Glutathione S-transferases and related proteins from pathogenic human parasites behave as immunomodulatory factors[J]. Immunol Lett, 2002,81(3):159-164. DOI: 10.1016/s0165-2478(02)00035-4.
[21] Tao NN, Zhou HZ, Tang H, et al. Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway[J]. Oncotarget, 2016,7(31):50117-50130. DOI: 10.18632/oncotarget. 10319.
[22] Ali-Osman F, Brunner JM, Kutluk TM, et al. Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas[J]. Clin Cancer Res, 1997,3 12 Pt 1:2253-2261.
[23] Goto S, Ihara Y, Urata Y, et al. Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi[J]. FASEB J, 2001,15(14):2702-2714. DOI: 10.1096/fj.01-0376com.
[24] Kamada K, Goto S, Okunaga T, et al. Nuclear glutathione S-transferase pi prevents apoptosis by reducing the oxidative stress-induced formation of exocyclic DNA products[J]. Free Radic Biol Med, 2004,37(11):1875-1884. DOI: 10.1016/j.freeradbiomed.2004.09.002.
[25] Arranz L, Caamaño JH, Lord JM, et al. Preserved immune functions and controlled leukocyte oxidative stress in naturally long-lived mice: possible role of nuclear factor kappa B[J]. J Gerontol A Biol Sci Med Sci, 2010,65(9):941-950. DOI: 10.1093/gerona/glq101.
[26] Lee JR, Seok CJ, Kim JS, et al. Expression of NF-kappaB and cytokines in chronic rejection of transplanted murine heart[J]. J Korean Med Sci, 2001,16(4):397-406. DOI: 10.3346/jkms.2001.16.4.397.
[27] Zhao N, Wang R, Zhou L, et al. MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3[J]. Mol Cancer, 2014, 13:35. DOI: 10.1186/1476-4598-13-35.
[28] Dong X, Liu F, Li M. Inhibition of nuclear factor κB transcription activity drives a synergistic effect of cisplatin and oridonin on HepG2 human hepatocellular carcinoma cells[J]. Anticancer Drugs, 2016,27(4):286-299. DOI: 10.1097/CAD.0000000000000329.
|